Clinical, Histological, and Molecular Markers Associated with Allograft Loss in Transplant Glomerulopathy Patients

Transplantation

Volumn 99, Issue 9, 2015, Pages 1912-1918

  Kamal, Layla ^a   Broin, Pilib O ^b   Bao, Yi ^a   Ajaimy, Maria ^a   Lubetzky, Michelle ^a   Gupta, Anjali ^a   De Boccardo, Graciela ^a   Pullman, James ^a   Golden, Aaron ^b,c   Akalin, Enver ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c YESHIVA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GRANULYSIN; IMMUNOGLOBULIN; MOLECULAR MARKER; MYCOPHENOLATE MOFETIL; PANEL REACTIVE ANTIBODY; PREDNISONE; TACROLIMUS; ALLOANTIBODY; GENETIC MARKER; HLA ANTIGEN;

ADULT; ARTICLE; BANFF INJURY SCORE; CHEMICAL PARAMETERS; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLOMERULOPATHY; GRAFT FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEAN FLUORESCENCE INTENSITY; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN TO CREATININE RATIO; SCORING SYSTEM; TRANSPLANT GLOMERULOPATHY; UPREGULATION; ADVERSE EFFECTS; AGED; BIOPSY; BLOOD; CHEMISTRY; DNA MICROARRAY; GENETIC MARKER; GENETIC TRANSCRIPTION; GENETICS; GRAFT REJECTION; IMMUNOLOGY; KIDNEY; KIDNEY TRANSPLANTATION; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; RETROSPECTIVE STUDY; SEROLOGY; TIME; TREATMENT OUTCOME;

ADULT; AGED; BIOPSY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKERS; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEROLOGIC TESTS; TIME FACTORS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 84944108630     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000598     Document Type: Article

References (32)

1. Husain S, Sis B. Advances in the understanding of transplant glomerulopathy. Am J Kidney Dis 2013;62(2):352.
2. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3(6):708.
3. Baid-Agrawal S, Farris AB 3rd, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011;80(8):879.
4. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006;6(8):1841.
5. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007;7(9):2124.
6. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008;86(5):681.
7. Kieran N, Wang X, Perkins J, et al. Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure. J Am Soc Nephrol 2009;20(10):2260.
8. Banfi G, Villa M, Cresseri D, Ponticelli C. The clinical impact of chronic transplant glomerulopathy in cyclosporine era. Transplantation 2005;80 (10):1392.
9. John R, Konvalinka A, Tobar A, Kim SJ, Reich HN, Herzenberg AM. Determinants of long-term graft outcome in transplant glomerulopathy. Transplantation 2010;90(7):757.
10. Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplan 2008;8(3):492.
11. Eng HS, Bennett G, Chang SH, et al. Donor human leukocyte antigen specific antibodies predict development and define prognosis in transplant glomerulopathy. Hum Immunol 2011;72(5):386.
12. Elster EA, Hawksworth JS, Cheng O, et al. Probabilistic (Bayesian) modeling of gene expression in transplant glomerulopathy. J Mol Diagn 2010;12(5):653.
13. Hayde N, Bao Y, Pullman J, et al. The clinical and genomic significance of donor-specific antibody-positive/c4d-negative and donor-specific antibodynegative/c4d-negative transplant glomerulopathy. Clin J Am Soc Nephrol 2013;8(12):2141.
14. Dean PG, Park WD, Cornell LD, Gloor JM, Stegall MD. Intragraft gene expression in positive crossmatch kidney allografts: ongoing inflammation mediates chronic antibody-mediated injury. Am J Transplant 2012;12(6): 1551.
15. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010;10(3):464.
16. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8(4):753.
17. Hayde N, Broin PO, Bao Y, et al. Increased intragraft rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies. In: Kidney Int 2014.
18. Pfoertner S, Jeron A, Probst-Kepper M, et al. Signatures of human regulatory T cells: an encounter with old friends and new players. Genome Biol 2006;7(7):R54.
19. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009;9(10):2312.
20. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014;14(2):272.
21. Akalin E, Dinavahi R, Dikman S, et al. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol 2007;2(6):1261.
22. Akalin E, Dikman S, Murphy B, Bromberg JS, Hancock WW. Glomerular infiltration by CXCR3+ ICOS + activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant 2003;3(9): 1116.
23. Goes N, Urmson J, Hobart M, Halloran PF. The unique role of interferongamma in the regulation of MHC expression on arterial endothelium. Transplantation 1996;62(12):1889.
24. Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007;7(12):2712.
25. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010;10(8):1812.
26. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithmfor antibodymediated microcirculation inflammation in kidney transplants. Am J Transplant 2012;12(5):1168.
27. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J AmSoc Nephrol 2001;12(3):574.
28. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007;7(7):1743.
29. Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012;94(2):172.
30. Billing H, Rieger S, Susal C, et al. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int 2012;25(11):1165.
31. Kahwaji J, Najjar R, Kancherla D, et al. Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab. Clin Transplant 2014;28(5):546.
32. Haas M, Mirocha J. Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy. Am J Transplant 2011;11(10):2123.